CARTITUDE-4 in Relapsed Multiple Myeloma

Results of the CARTITUDE-4 phase 3 clinical trial

Dr. Binod Dhakal presents the results of the CARTITUDE-4 phase 3 clinical trial were presented, evaluating the efficacy of cilta-cel, a BCMA-directed CAR-T cell therapy, compared to standard of care treatment in patients with relapsed or refractory multiple myeloma. The trial included patients who were refractory to lenalidomide and had received one to three prior lines of therapy. The primary endpoint of progression-free survival (PFS) was significantly improved in the cilta-cel arm compared to the standard of care arm. The hazard ratio for disease progression or death was 0.26, and the median PFS was not reached in the cilta-cel arm compared to 11.8 months in the standard of care arm. The overall response rate and depth of response were also significantly higher with cilta-cel. The safety profile of cilta-cel was manageable, with grade 3 or higher adverse events occurring in most patients, but generally recovering. The study suggests that cilta-cel has the potential to become a new standard of care for patients with relapsed or refractory multiple myeloma after the first relapse.

• The CARTITUDE-4 phase 3 clinical trial evaluated the efficacy of cilta-cel in patients with relapsed or refractory multiple myeloma.
• Cilta-cel is a BCMA-directed CAR-T cell therapy.
• The trial included patients who were refractory to lenalidomide and had received one to three prior lines of therapy.
• The primary endpoint of progression-free survival (PFS) was significantly improved with cilta-cel compared to the standard of care.
• The hazard ratio for disease progression or death was 0.26, indicating a significant reduction in risk.
• The median PFS was not reached in the cilta-cel arm and was 11.8 months in the standard of care arm.
• The overall response rate and depth of response were significantly higher with cilta-cel.
• The safety profile of cilta-cel was manageable, with most adverse events being grade 3 or lower and generally recovering.
• The study suggests that cilta-cel has the potential to become a new standard of care for patients with relapsed or refractory multiple myeloma after the first relapse.

Authors:
Binod Dhakal, Kwee Yong, Simon J. Harrison, Maria-Victoria Mateos, Philippe Moreau, Niels W.C.J. van de Donk, Surbhi Sidana, Rakesh Popat, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Jordan Mark Schecter, Katherine Li, Enrique Zudaire, Ying Chen, Jane Gilbert, Lida Bubuteishvili-Pacaud, Nitin Patel, Jesús San-Miguel, Hermann Einsele

Clinical Trial: NCT04181827